Diabetic Retinopathy (DR) Program: SURYA-101
Understanding Diabetic Retinopathy
Diabetic retinopathy (DR) is a serious complication of diabetes that affects the blood vessels in the retina—the light-sensitive tissue at the back of the eye. Over time, high blood sugar levels can damage these delicate blood vessels, leading to vision problems and, in severe cases, blindness.
Increased vascular permeability: Blood vessels become 'leaky,' allowing fluid and proteins to seep into the retina
Breakdown of the blood-retinal barrier: The protective barrier that normally keeps harmful substances out of the retina is compromised
Cell damage: Retinal neurons, endothelial cells, and pericytes (cells that support blood vessels) can undergo apoptosis (programmed cell death)
Elevated VEGF and IL-6: These signaling molecules promote abnormal blood vessel growth and inflammation
Inflammation: Chronic inflammation contributes to progressive damage
Neovascularization and hemorrhage: Abnormal new blood vessels may form and bleed, potentially leading to vision loss or retinal detachment
What is SURYA-101?
SURYA-101 is an investigational lipid mediator-based approach being developed for diabetic retinopathy. It represents a different strategy from current anti-VEGF injection therapies.
SURYA-101 is described as a mixture of LXA4 (Lipoxin A4), NPD1 (Neuroprotectin D1), and RSVs (Resolvins) in a specific ratio. This combination is intended to be anti-angiogenic (inhibit abnormal blood vessel growth), cytoprotective (protect cells), anti-inflammatory, and to enhance BDNF (brain-derived neurotrophic factor) while inhibiting VEGF production.
The approach centers on LXA4/AA (Lipoxin A4 derived from arachidonic acid), a low molecular weight lipid concept. Research indicates that LXA4 may block NFkB, VEGF, angiopoietin-2, and IL-6. Studies suggest that LXA4, BDNF, AA, and DHA levels are low in diabetic retinopathy patients.
How it may work (investigational)
Proposed mechanisms of action
Information presented represents historical observations and preclinical research. Results may not be generalizable and do not predict future clinical outcomes.
How this differs from current therapy
Category comparison (not a claim of superiority)
Current standard treatments for diabetic retinopathy include anti-VEGF monoclonal antibody injections (such as ranibizumab, aflibercept, and bevacizumab). These treatments work by neutralizing VEGF after it is produced, requiring repeated injections into the eye.
| Aspect | Current Anti-VEGF Injections | SURYA-101 (Investigational Intent) |
|---|---|---|
| Mechanism | Neutralizes VEGF after production | Aims to inhibit VEGF production |
| Administration | Intravitreal injections | Potential for eye-drop development (intent) |
| Frequency | Multiple injections over time | Potentially fewer treatments (intent) |
| Additional targets | VEGF focused | Multiple pathways (VEGF, NFkB, IL-6, BDNF) |
| Status | FDA approved, widely used | Investigational, preclinical |
Development Status & Roadmap
Current status and planning estimates
Funding estimate: Approximately $1M investment needed (planning estimate)
FAQs for Patients & Caregivers
Common questions about our diabetic retinopathy program
Important Notice: SURYA-101 is investigational and not approved by the FDA or any regulatory authority. It is not available as an approved treatment option.
Urgent symptoms: If you experience sudden vision changes, flashes, floaters, or vision loss, seek immediate medical care. This is a medical emergency.
Want to learn more?
Request our information deck or connect with our team to discuss the diabetic retinopathy program.